Your browser version may not work well with NCBI's Web applications. More information
here...
-
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Engler TA,
Henry JR,
Malhotra S,
Cunningham B,
Furness K,
Brozinick J,
Burkholder TP,
Clay MP,
Clayton J,
Diefenbacher C,
Hawkins E,
Iversen PW,
Li Y,
Lindstrom TD,
Marquart AL,
McLean J,
Mendel D,
Misener E,
Briere D,
O'Toole JC,
Porter WJ,
Queener S,
Reel JK,
Owens RA,
Brier RA,
Eessalu TE,
Wagner JR,
Campbell RM,
Vaughn R.
Lilly Research Laboratories, A Division of Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. Engler_Thomas@lilly.com
Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.
PMID: 15267232 [PubMed - indexed for MEDLINE]
-
Related Articles
-
Related Reviews